BioCentury | Mar 9, 2015
Finance

Column's creations

...early stage drug discovery based on "unique scientific platforms with the potential to deliver multiple breakthrough therapeutics,"...
BioCentury | Sep 4, 2006
Company News

Breakthrough Therapeutics, MolecularMD deal

...NVS; SWX:NOVN, Basel, Switzerland) markets Gleevec imatinib to treat CML and gastrointestinal stromal tumors (GIST). Breakthrough Therapeutics LLC...
BioCentury | Aug 28, 2006
Company News

Cellumen board of directors update

...Cellumen Inc. , Pittsburgh, Penn. Business: Proteomics Appointed: Rosemary Mazanet, CEO of Breakthrough Therapeutics LLC and acting CEO...
BioCentury | Jun 5, 2006
Product Development

ALL/CML pipeline

...Gleevec Heat shock protein 70 (HSP70) vaccine derived from autologous tumor cells CML Ph II Breakthrough Therapeutics...
BioCentury | Jan 9, 2006
Clinical News

VAX100: Phase I/II data

...markets Gleevec imatinib. Data were presented at the American Society of Hematology meeting in Atlanta. Breakthrough Therapeutics LLC...
BioCentury | Jan 9, 2006
Clinical News

VAX100: Phase II started

...40 to 80 patients treated with Gleevec . Novartis AG (NVS; SWX:NOVN) markets Gleevec imatinib. Breakthrough Therapeutics LLC...
BioCentury | May 12, 2005
Company News

Access CEO Gray resigns

...AKC said Kerry Gray resigned as president, CEO and a director. Rosemary Mazanet, CEO of Breakthrough Therapeutics...
BioCentury | Mar 7, 2005
Clinical News

VAX100 cancer data

...imatinib is marketed by Novartis AG (NVS; SWX:NOVN, Basel, Switzerland). Data were published in Lancet. Breakthrough Therapeutics LLC...
BioCentury | Oct 18, 2004
Regulation

Two mouths, if not one voice

...better understanding of the potential challenges and benefits, FDA and EMEA will focus initially on breakthrough therapeutics...
BioCentury | Sep 5, 1995
Strategy

Back to School 1995: Old-fashioned values

Every year at Labor Day, BioCentury puts on its schoolmarm glasses and lectures on the issues that will consume the industry's attention as everyone settles back to work after the summer holiday. For the past...
Items per page:
1 - 10 of 10
BioCentury | Mar 9, 2015
Finance

Column's creations

...early stage drug discovery based on "unique scientific platforms with the potential to deliver multiple breakthrough therapeutics,"...
BioCentury | Sep 4, 2006
Company News

Breakthrough Therapeutics, MolecularMD deal

...NVS; SWX:NOVN, Basel, Switzerland) markets Gleevec imatinib to treat CML and gastrointestinal stromal tumors (GIST). Breakthrough Therapeutics LLC...
BioCentury | Aug 28, 2006
Company News

Cellumen board of directors update

...Cellumen Inc. , Pittsburgh, Penn. Business: Proteomics Appointed: Rosemary Mazanet, CEO of Breakthrough Therapeutics LLC and acting CEO...
BioCentury | Jun 5, 2006
Product Development

ALL/CML pipeline

...Gleevec Heat shock protein 70 (HSP70) vaccine derived from autologous tumor cells CML Ph II Breakthrough Therapeutics...
BioCentury | Jan 9, 2006
Clinical News

VAX100: Phase I/II data

...markets Gleevec imatinib. Data were presented at the American Society of Hematology meeting in Atlanta. Breakthrough Therapeutics LLC...
BioCentury | Jan 9, 2006
Clinical News

VAX100: Phase II started

...40 to 80 patients treated with Gleevec . Novartis AG (NVS; SWX:NOVN) markets Gleevec imatinib. Breakthrough Therapeutics LLC...
BioCentury | May 12, 2005
Company News

Access CEO Gray resigns

...AKC said Kerry Gray resigned as president, CEO and a director. Rosemary Mazanet, CEO of Breakthrough Therapeutics...
BioCentury | Mar 7, 2005
Clinical News

VAX100 cancer data

...imatinib is marketed by Novartis AG (NVS; SWX:NOVN, Basel, Switzerland). Data were published in Lancet. Breakthrough Therapeutics LLC...
BioCentury | Oct 18, 2004
Regulation

Two mouths, if not one voice

...better understanding of the potential challenges and benefits, FDA and EMEA will focus initially on breakthrough therapeutics...
BioCentury | Sep 5, 1995
Strategy

Back to School 1995: Old-fashioned values

Every year at Labor Day, BioCentury puts on its schoolmarm glasses and lectures on the issues that will consume the industry's attention as everyone settles back to work after the summer holiday. For the past...
Items per page:
1 - 10 of 10